Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Asset Writedowns and Impairment (2016 - 2025)

STRATA Skin Sciences' Asset Writedowns and Impairment history spans 13 years, with the latest figure at -$166000.0 for Q3 2025.

  • For Q3 2025, Asset Writedowns and Impairment fell 304.88% year-over-year to -$166000.0; the TTM value through Sep 2025 reached -$282000.0, down 244.62%, while the annual FY2024 figure was -$182000.0, 65.45% down from the prior year.
  • Asset Writedowns and Impairment for Q3 2025 was -$166000.0 at STRATA Skin Sciences, down from $166000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $166000.0 in Q2 2025 and bottomed at -$282000.0 in Q4 2024.
  • The 5-year median for Asset Writedowns and Impairment is $20000.0 (2021), against an average of -$11500.0.
  • The largest YoY upside for Asset Writedowns and Impairment was 700.0% in 2021 against a maximum downside of 2800.0% in 2021.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $27000.0 in 2021, then surged by 207.41% to $83000.0 in 2022, then rose by 14.46% to $95000.0 in 2023, then tumbled by 396.84% to -$282000.0 in 2024, then soared by 41.13% to -$166000.0 in 2025.
  • Per Business Quant, the three most recent readings for SSKN's Asset Writedowns and Impairment are -$166000.0 (Q3 2025), $166000.0 (Q2 2025), and -$282000.0 (Q4 2024).